PASG (Passage Bio) Debt-to-Asset : 0.16 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PASG Passage Bio Inc PASG
30 GF Score
Price $4.40
! 2 Warning Signs
View Full Analysis

What is Passage Bio Debt-to-Asset?

Passage Bio PASG 30 Debt-to-Asset is 0.16 as of Mar. 2026. GuruFocus rates PASG with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Passage Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $1.15 Mil. Passage Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $4.61 Mil. Passage Bio's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2026 was $36.46 Mil. Passage Bio's debt to asset for the quarter that ended in Mar. 2026 was 0.16.

Passage Bio  (NAS:PASG) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Passage Bio Debt-to-Asset Related Terms

Passage Bio Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Passage Bio's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Passage Bio Debt-to-Asset Chart

Passage Bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial 0.00 0.11 0.18 0.25 0.39

Passage Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.29 0.31 0.33 0.39 0.16

PASG vs OTLC, KTTA, LSTA: Debt-to-Asset Comparison

For the Biotechnology subindustry, Passage Bio's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Passage Bio Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Passage Bio's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Passage Bio's Debt-to-Asset falls into.


PASG
30GF Score
Passage Bio Inc PASG
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Passage Bio Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Passage Bio's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(3.567 + 20.443) / 62.281
=0.39

Passage Bio's Debt-to-Asset for the quarter that ended in Mar. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(1.149 + 4.606) / 36.462
=0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.16 mean?
Passage Bio (PASG) has a Debt-to-Asset of 0.16 as of Mar. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Passage Bio and its competitors.
Is Passage Bio's Debt-to-Asset too high?
Passage Bio's current Debt-to-Asset is 0.16. Overall, Passage Bio has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Passage Bio's Debt-to-Asset compare to OTLC and KTTA?
Passage Bio's Debt-to-Asset of 0.16 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Passage Bio and its competitors. Passage Bio's current Debt-to-Asset is 0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Passage Bio stock overvalued right now?
Passage Bio (PASG) has a current Debt-to-Asset of 0.16. The current Debt-to-Asset is 0.16. Passage Bio's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Passage Bio (PASG), the current Debt-to-Asset is 0.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Passage Bio Business Description

Address 2005 Market Street, 39th Floor, One Commerce Square, Philadelphia, PA, USA, 19103
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
30GF Score

Get the complete analysis for PASG

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.40
Price